In this week’s S&P 500 healthcare earnings roundup, 21 of 24 companies beat earnings expectations, while three fell short. On ...

Amgen’s adjusted earnings per share reached $4.90, exceeding expectations and marking a 24% increase year-over-year. Total ...

Beachgoers, including a father and son, banded together to help a great white shark that became stranded in shallow waters of ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

Deep-pocketed investors have adopted a bearish approach towards Amgen AMGN, and it's something market players shouldn't ...

The FDA has freed Amgen’s mysterious early-stage obesity asset from a clinical hold, with the phase 1 study now enrolling ...

Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

Fuller & Thaler Asset Management upped its Amgen stake by 12.9% in Q4, signaling continued faith in the biotech juggernaut. The firm now holds 36,971 shares valued at $9.64 million, a clear vote of ...

Amgen (NASDAQ:AMGN) reported a 24% rise in first-quarter profit, fueled by strong product sales, while reaffirming full-year ...